Effect of hydromorphone on cardiac electrophysiology in patients undergoing surgery: a randomized controlled trial.

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044487

Enrollment

Unknown

Registered

2021-03-23

Start date

2021-03-22

Completion date

Unknown

Last updated

2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electrophysiology of heart

Interventions

high-dose hydromorphone group:injected with 1.0 mg and 1.5 mg of hydromorphone

????????:injected with 1.0 mg and 1.0 mg of hydromorphone

control group:Inject the same amount of normal saline

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Preoperative cardiopulmonary function and electrolyte were normal, ECG was normal, QT interval and heart rate corrected QT interval < 440 ms, no antiarrhythmic drugs, ß-blockers, antidepressants and other drugs to extend QT interval, no endocrine diseases.

Exclusion criteria

Exclusion criteria: Hypersensitivity to hydromorphone, history of asthma, and difficulty in measuring ECG waveform.

Design outcomes

Primary

Measure	Time frame
Electrocardiogram;	—

Countries

China

Contacts

Public ContactYanqiu Liu

Guiyang Fourth People's Hospital

1150725102@qq.com+86 18198618386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026